In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Long-term prognosis of patients with infectious endocarditis: a 14-year longitudinal study

Session Poster Session 3

Speaker Ines Aguiar Ricardo

Event : Acute Cardiovascular Care 2016

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease
  • Session type : Poster Session

Authors : I Aguiar Ricardo (Lisbon,PT), P Carrilho-Ferreira (Lisbon,PT), J Rigueira (Lisbon,PT), J Agostinho (Lisbon,PT), I Santos Goncalves (Lisbon,PT), N Andre (Lisbon,PT), T Guimaraes (Lisbon,PT), G Lima Da Silva (Lisbon,PT), R Francisco (Lisbon,PT), M Nobre Menezes (Lisbon,PT), J Fausto Pinto (Lisbon,PT)

I Aguiar Ricardo1 , P Carrilho-Ferreira1 , J Rigueira1 , J Agostinho1 , I Santos Goncalves1 , N Andre1 , T Guimaraes1 , G Lima Da Silva1 , R Francisco1 , M Nobre Menezes1 , J Fausto Pinto1 , 1Hospital Universitário de Santa Maria/CHLN, CAML, CCUL,Faculdade de Medicina, Universidade de Lisboa, Cardiology - Lisbon - Portugal ,

European Heart Journal Supplement ( 2010 ) 12 ( Supplement F ), F258

Purpose: Despite significant advances in the diagnosis and management of most cardiovascular disorders, infectious endocarditis still has a very high mortality. This study aims to evaluate the long-term prognosis of patients admitted due to infectious endocarditis.
Methods: We included consecutive patients admitted to the Cardiology department of a university hospital between 2001 and 2015 with a diagnosis of infectious endocarditis, established by the Duke criteria. We collected information on demographic, clinical, laboratory, echocardiographic, and microbiologic parameters and their association with 2 years-mortality rate was determined by Cox regression analysis.
Results: One hundred and twenty patients were included (67.5% male; age 65±14 years; follow-up 31.9±38.4 months). The mortality rate within 2 years was 43% (52 patients).
Several parameters were associated with long-term prognosis, including: a baseline RCP> 13mg/dL (p=0.007), a baseline NT-proBNP level > 2500 pg/mL (p=0.016), infection of a bioprosthesis (p<0.001), significant dysfunction of prosthesis (p=0.009), the presence of cardiac fistula (p=0.036) and indication for surgery (p=0.037).
The occurrence of several complications during hospitalization, such as class IV heart failure (p<0.001), shock (p<0.001), the need for renal replacement therapy (p<0.001) and stroke (p=0.004) also presented a higher mortality rate.
On multivariate Cox regression analysis the only independent predictors of mortality within 2 years were the occurrence of shock [hazard ratio (HR)=8.99; 95% CI 3.02-24.31; p<0.001], stroke (HR = 3,04; 95% CI 1.03-6.52, p=0.043) and the presence of surgery’s indication [HR=9.02; 95% CI 2.68-60.11, p=0.001]. On the other hand, patients submitted to valve surgery had a better prognosis presenting a lower mortality within 2 years (p=0.01).
Conclusions: In this study, infectious endocarditis presented a high 2 years-mortality rate. Several clinical and laboratory parameters were associated to a higher mortality rate. The occurrence of shock or stroke during hospitalization and the presence of indication for surgery were identified as the only independent predictors of adverse long-term prognosis, while performing valve surgery had a protective effect.
Thus, these parameters may be considered to be included in prognostic stratification of patients with infectious endocarditis.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are